Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleContinuing Education

Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations

Eric J. Schockling, Mary Beth Farrell, Monica Embry-Dierson, Jaime Warren and Scott Jerome
Journal of Nuclear Medicine Technology June 2023, 51 (2) 90-98; DOI: https://doi.org/10.2967/jnmt.123.265416
Eric J. Schockling
1Outpatient Cardiovascular Diagnostics, Norton Healthcare, LLC, Louisville, Kentucky;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Beth Farrell
2Intersocietal Accreditation Commission, Ellicott City, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Embry-Dierson
3Noninvasive Cardiology, Norton Audubon Hospital, Louisville, Kentucky;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaime Warren
4MedAxiom, Neptune Beach, Florida; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Jerome
5University of Maryland School of Medicine, Westminster, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Semiquantitative visual grading. Both planar and SPECT images are used to visually score degree of cardiac amyloidosis. Amount of 99mTc-pyrophosphate uptake in myocardium is compared with that in ribs. Grade 0 (normal) = no myocardial uptake and normal bone uptake; grade 1 (equivocal) = myocardial uptake less than rib uptake; grade 2 (abnormal and suggestive of cardiac amyloidosis) = myocardial and rib uptake equal; grade 3 (abnormal and strongly suggestive of cardiac amyloidosis) = myocardial uptake greater than rib uptake; PYP = pyrophosphate.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Correct region-of-interest placement for H/CL ratio. To accurately calculate H/CL ratio, circular region of interest (ROI) is placed over myocardium on 3-h anterior planar 99mTc-pyrophosphate image (blue circle). Size of heart region should be maximized to cover entire myocardium. For contralateral lung, equal-sized ROI is placed on opposite side of sternum on flat area of ribs (white circle). H/CL ratio is calculated by dividing heart region mean counts by contralateral chest region mean counts. (Courtesy of Saurabh Malhotra, MD, MPH.)

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    H/CL ratio incorrect region-of-interest placement. Three-hour anterior planar 99mTc-pyrophosphate images were used to demonstrate impact of incorrect region-of-interest placement on H/CL ratio. (A) Correct heart and contralateral-lung region-of-interest placement resulted in H/CL ratio of 1.18, which is negative for amyloidosis. (B) Incorrect heart region-of-interest placement including sternal activity but correct contralateral-lung region-of-interest placement. H/CL ratio was falsely elevated at 1.91, suggesting cardiac amyloidosis. (C) Correct heart region-of-interest placement but incorrect contralateral-lung region-of-interest placement over curvature of ribs resulting in falsely decreased ratio of 0.94 because of increased activity in contralateral-lung region of interest. (D) Correct heart region-of-interest placement but incorrect contralateral region-of-interest placement including sternal activity. Calculated H/CL ratio was falsely decreased at 0.67. Heart region of interest = 1. Contralateral-lung region of interest = 2.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    99mTc-pyrophosphate image comparison at 1 vs. 3 h. (A) Anterior (left) and left anterior oblique (right) images acquired 1 h after injection. (B) Anterior (left) and left anterior oblique (right) images acquired 3 h after injection. Images acquired 3 h after injection demonstrate better soft-tissue clearance and greater bone uptake and definition than images acquired 1 h after injection. Hardly any bone uptake is discernable in 1-h images. In addition, myocardial uptake is similar on both 1- and 3-h images because peak myocardial uptake of 99mTc-pyrophosphate occurs about 1 h after injection. Peak bone uptake occurs 2–3 h after injection.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Planar vs. SPECT blood pool. On planar 99mTc-pyrophosphate images, blood pool cannot be differentiated from myocardial uptake. (A) Anterior planar image demonstrating diffuse uptake assumed to be myocardial uptake. Planar-only imaging cannot be used to differentiate blood-pool uptake from myocardial uptake. (B) SPECT images immediately after acquisition of planar images showing that 99mTc-pyrophosphate uptake is not localized to myocardium but is within ventricular cavity blood pool. Circle denotes coronal image best demonstrating residual blood pool. (Reprinted from (1).)

Tables

  • Figures
    • View popup
    TABLE 1.

    99mTc-Pyrophosphate Cardiac Amyloidosis Imaging Parameters

    ParameterCharacteristicsStandard/optional/preferred
    Camera typeLarge-field-of-view γ-cameraStandard
    Cadmium zinc tellurideOptional*
    Energy peak140 keVStandard
    Energy window15%–20%Standard
    CollimatorLow-energy, all-purposeStandard
    Patient positionSupineStandard
    Field of viewHeart/chestStandard
    Injection-to-imaging time3 hStandard
    1 hOptional
    Planar
     Acquisition typeStaticStandard
    Whole-body imagingOptional†
     Detector configuration90°Standard
     ViewsAnterior and left lateralStandard
     Number of views2Standard
     Counts per view750,000Standard
     Matrix256 × 256Standard
     Magnification1.46
    SPECT or SPECT/CT*
     Acquisition typeStep and shoot or continuousStandard
     Patient positionSupineStandard
    UprightOptional
     Orbit180°/90°Standard
    360°/180°Optional
     Matrix128 × 128 (minimum, 64 × 64)Standard
     Magnification1.46 (180° orbit)Standard
    1.0 (360° orbit)Optional
     Pixel size2.3–6.5 mmStandard
     Projections per detector40/32Standard
     Time per projection20 s/25 sStandard
     CT attenuation correctionHeartPreferred
    • ↵* Parameters defined for γ-cameras as parameters for cadmium-zinc-telluride cameras have not been firmly established.

    • ↵† Whole-body imaging is not useful when imaging with 99mTc-pyrophosphate. However, when using 99mTc-hydroxymethylenediphosphonate or 99mTc-DPD, whole-body imaging is useful to demonstrate soft-tissue uptake.

    • View popup
    TABLE 2.

    Semiquantitative Visual Scoring of 99mTc-Pyrophosphate Uptake in Myocardium Versus Ribs

    GradeDescription
    0No myocardial uptake and normal bone uptake
    1Myocardial uptake less than rib uptake
    2Myocardial uptake equal to rib uptake
    3Myocardial uptake greater than rib uptake, with mild or absent rib uptake
    • View popup
    TABLE 3.

    Sensitivity, Specificity, and Predictive Value Refresher

    MeasureDescriptionFormula
    SensitivityProbability that result will be positive when disease is presentTP/(TP + FN)
    SpecificityProbability that result will be negative when disease is absentTN/(TN + FP)
    AccuracyNumber of correct findings(TP + TN)/(TP + TN + FP + FN)
    Positive predictive valueProbability that patients with positive result truly have diseaseTP/(TP + FP)
    Negative predictive valueProbability that patients with negative result do not have diseaseTN/(TN+FN)
    • TP = patients with positive result who have disease; FN = patients with negative result who have disease; TN = patients with negative result who do not have disease; FP = patients with positive result who do not have disease.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 51 (2)
Journal of Nuclear Medicine Technology
Vol. 51, Issue 2
June 1, 2023
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations
Eric J. Schockling, Mary Beth Farrell, Monica Embry-Dierson, Jaime Warren, Scott Jerome
Journal of Nuclear Medicine Technology Jun 2023, 51 (2) 90-98; DOI: 10.2967/jnmt.123.265416

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations
Eric J. Schockling, Mary Beth Farrell, Monica Embry-Dierson, Jaime Warren, Scott Jerome
Journal of Nuclear Medicine Technology Jun 2023, 51 (2) 90-98; DOI: 10.2967/jnmt.123.265416
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • BRIEF REVIEW OF CARDIAC AMYLOIDOSIS
    • PROCEDURE EVOLUTION
    • CURRENT RECOMMENDED PROTOCOL
    • ACQUISITION
    • PROCESSING AND QUANTIFICATION
    • INTERPRETATION
    • TECHNICAL CONSIDERATIONS
    • 99MTC-PYROPHOSPHATE KINETICS
    • INJECTION-TO-IMAGING DELAY OF 1–3 HOURS
    • PLANAR IMAGING VERSUS SPECT
    • TECHNICAL CONSIDERATIONS IN APPLICATION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • SPECT Views for Cardiac Amyloidosis Imaging
  • Reply to "SPECT Views for Cardiac Amyloidosis Imaging"
  • Lets Meet in the Windy City!
  • Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment
  • Cardiac Amyloidosis Imaging, Part 1: Amyloidosis Etiology and Image Acquisition
  • Google Scholar

More in this TOC Section

  • Illuminating the Hidden: Standardizing Cardiac MIBG Imaging for Sympathetic Dysfunction
  • PET/CT Case Series: Unmasking the Mystery of Cardiac Sarcoidosis
  • Delivery Methods of Radiopharmaceuticals: Exploring Global Strategies to Minimize Occupational Radiation Exposure
Show more Continuing Education

Similar Articles

Keywords

  • 3-h imaging
  • heart–to–contralateral-lung ratio (H/CL)
  • semiquantitative scoring
  • blood pool
  • cardiac amyloidosis
SNMMI

© 2025 SNMMI

Powered by HighWire